Elevance EVP logs tax-withheld stock and RSU award

Elevance Health EVP Peter D. Haytaian reported equity compensation activity in company common stock.

Rhea-AI Filing Summary

Elevance Health EVP Peter D. Haytaian reported equity compensation activity in company common stock. On March 3, 2026, 446 shares were withheld at $284.03 per share, and on March 2, 2026, 1,201 shares were withheld at $294.07 per share to cover tax liabilities upon vesting of previously granted restricted stock. Also on March 2, he received a grant of 2,865 performance-based restricted share units as an award, bringing his directly held stake to 27,668 shares after these transactions.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Haytaian Peter D

Role EVP & Pres Carelon & CarelonRx

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	446	$284.03	$127K
Exercise Price or Tax Liability	Common Stock	1,201	$294.07	$353K
Grant/Award	Common Stock	2,865	$0.00	$0.00

Holdings After Transaction: Common Stock — 27,222 shares (Direct)

Footnotes (2)

1. F1. PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK.
2. F2. Represents performance based restricted share units. Restrictions lapsed on 3/2/2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Elevance Health (ELV) executive Peter D. Haytaian report?

Peter D. Haytaian reported tax-withholding dispositions and an equity award. Two transactions withheld 446 and 1,201 shares to satisfy tax obligations, and he received 2,865 performance-based restricted share units, increasing his directly held Elevance Health common stock to 27,668 shares after these activities.

Were Peter D. Haytaian’s Elevance Health Form 4 transactions open-market sales?

No, the dispositions were not open-market sales. The Form 4 states code F transactions, which are shares withheld to pay tax liabilities upon vesting of restricted stock, rather than discretionary market sales, according to the tax-withholding footnote and transaction descriptions.

What equity award did Elevance Health grant to Peter D. Haytaian on March 2, 2026?

On March 2, 2026, Peter D. Haytaian received 2,865 performance-based restricted share units. A footnote explains these units are performance-based RSUs whose restrictions lapsed on that date, reflecting previously granted compensation that has now vested into common stock.

How many Elevance Health shares does Peter D. Haytaian own after the reported Form 4 transactions?

After the reported Form 4 transactions, Peter D. Haytaian directly owns 27,668 shares of Elevance Health common stock. This figure reflects the impact of the tax-withholding dispositions and the vesting and award of performance-based restricted share units disclosed in the filing.

What do the code F transactions mean in Elevance Health executive Peter D. Haytaian’s Form 4?

Code F indicates shares were surrendered to cover tax or exercise costs. In this Form 4, shares of Elevance Health stock were withheld to satisfy tax liabilities associated with the vesting of previously granted restricted stock, rather than being sold on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 04:57 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Haytaian Peter D

(Last) (First) (Middle)

220 VIRGINIA AVENUE

(Street)

INDIANAPOLIS IN 46204

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elevance Health, Inc. [ ELV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Pres Carelon & CarelonRx

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		F		1,201(1)	D	$294.07	24,803	D
Common Stock	03/02/2026		A		2,865(2)	A	$0	27,668	D
Common Stock	03/03/2026		F		446(1)	D	$284.03	27,222	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK.

2. Represents performance based restricted share units. Restrictions lapsed on 3/2/2026.

Remarks:

	/s/ Kathleen S. Kiefer, Attorney in fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.